Seqens Seqens

X
menu

    Market Place

    Market Place

    Post Enquiry

    Post Enquiry
    menu
    [{"orgOrder":0,"company":"TaiGen Biotechnology","sponsor":"Luminarie","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"TaiGen Out-Licensed Taigexyn\u00ae to Luminarie Canada for Canada, Australia and New Zealand","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Approved","country":"TAIWAN","productType":"Small molecule","productStatus":"Approved","date":"September 2020","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Approved"},{"orgOrder":0,"company":"TaiGen Biotechnology","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"TaiGen Filed U.S IND for Its Influenza Antiviral TG-1000","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase I","country":"TAIWAN","productType":"Undisclosed","productStatus":"New Molecular Entity","date":"October 2020","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase I"},{"orgOrder":0,"company":"TaiGen Biotechnology","sponsor":"GPCR Therapeutics","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"TaiGen Partners with GPCR to Develop Burixafor & Taigexyn\u00ae","therapeuticArea":"Immunology","highestDevelopmentStatus":"Phase II","country":"TAIWAN","productType":"Small molecule","productStatus":"New Molecular Entity","date":"November 2020","url1":"","url2":"","graph1":"Immunology","graph2":"Phase II"},{"orgOrder":0,"company":"TaiGen Biotechnology","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"TaiGen Announces FDA Approval of IND for Its Flu Antiviral TG-1000","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase I","country":"TAIWAN","productType":"Undisclosed","productStatus":"New Molecular Entity","date":"November 2020","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase I"},{"orgOrder":0,"company":"TaiGen Biotechnology","sponsor":"JIAOZUO JOINCARE BIOTECHNOLOGICAL CO LTD","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"$2.9 million","newsHeadline":"TaiGen Enters Exclusive License Agreement with Joincare for TG-1000 in China","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase II","country":"TAIWAN","productType":"Small molecule","productStatus":"New Molecular Entity","date":"March 2023","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase II"},{"orgOrder":0,"company":"TaiGen Biotechnology","sponsor":"Y.S.P. Industries M Sdn Bhd","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"TaiGen Enters Exclusive License Agreement with YSP","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase II","country":"TAIWAN","productType":"Small molecule","productStatus":"New Molecular Entity","date":"October 2023","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase II"},{"orgOrder":0,"company":"TaiGen Biotechnology","sponsor":"Joincare Pharmaceutical","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"TaiGen Successfully Completes TG-1000 Phase III Study","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase III","country":"TAIWAN","productType":"Small molecule","productStatus":"New Molecular Entity","date":"April 2024","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase III"}]

    Find Clinical Drug Pipeline Developments & Deals by TaiGen Biotechnology

    Menu

    TaiGen Biotechnology

    EVENTS

    • Webinars & Exhibitions

    PRESENTATION(s)

    VIDEO(s)

    DIGITAL CONTENT

    DEVELOPMENTS

    PharmaCompass
    Loading...

    All Data

    Previous
    Next
    Filters Filter
    ×
    FILTER:
    filter Company
      filter Sponsor
        filter Country
          filter Therapeutic Area
            filter Study Phase

              Active Filter(s):

              refreshFilters
              refreshReset Filter
              refresh Reset Filter
              price-trend All Developments

              Companies By Therapeutic Area

              Development Status

              TaiGen Biotechnology

              Contact Supplier
              • Development Update
              Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE
              Post an Enquiry Post an Enquiry
              Flag Taiwan
              Virtual Booth Virtual Booth
              Digital Content Digital Content

              TaiGen Successfully Completes TG-1000 Phase III Study

              Details:

              TG-1000 is a prodrug of TG-0527, a new molecular entity and a potent cap-dependent endonuclease inhibitor being investigated in adult and adolescent patients with uncomplicated acute influenza infection.

              Lead Product(s): TG-1000

              Therapeutic Area: Infections and Infectious Diseases Product Name: TG-1000

              Highest Development Status: Phase III Product Type: Small molecule

              Partner/Sponsor/Collaborator: Joincare Pharmaceutical

              Deal Size: Not Applicable Upfront Cash: Not Applicable

              Deal Type: Not Applicable April 17, 2024

              ASK
              US
              PHARMACOMPASS
              Upload
              your Pipeline Activity

              TaiGen Biotechnology

              Contact Supplier
              • Deals
              Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE
              Post an Enquiry Post an Enquiry
              Flag Taiwan
              Virtual Booth Virtual Booth
              Digital Content Digital Content

              TaiGen Enters Exclusive License Agreement with YSP

              Details:

              Under the agreement, Y.S.P. will develop and commercialize TaiGen's new small molecule drug, TG-1000, a virus replication inhibitor, for infections, in Malaysia and Singapore.

              Lead Product(s): TG-1000

              Therapeutic Area: Infections and Infectious Diseases Product Name: TG-1000

              Highest Development Status: Phase II Product Type: Small molecule

              Partner/Sponsor/Collaborator: Y.S.P. Industries M Sdn Bhd

              Deal Size: Undisclosed Upfront Cash: Undisclosed

              Deal Type: Licensing Agreement October 10, 2023

              ASK
              US
              PHARMACOMPASS
              Upload
              your Pipeline Activity

              TaiGen Biotechnology

              Contact Supplier
              • Deals
              Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE
              Post an Enquiry Post an Enquiry
              Flag Taiwan
              Virtual Booth Virtual Booth
              Digital Content Digital Content

              TaiGen Enters Exclusive License Agreement with Joincare for TG-1000 in China

              Details:

              Joincare will develop and commercialize TG-1000, a novel pan-influenza antiviral by interrupting viral replication and transmission via a cap-snatching mechanism, revealing efficacy against influenza-A, influenza-B, avian flu H7N9, and Tamiflu-resistant viruses, in china.

              Lead Product(s): TG-1000

              Therapeutic Area: Infections and Infectious Diseases Product Name: TG-1000

              Highest Development Status: Phase II Product Type: Small molecule

              Partner/Sponsor/Collaborator: JIAOZUO JOINCARE BIOTECHNOLOGICAL CO LTD

              Deal Size: Undisclosed Upfront Cash: $2.9 million

              Deal Type: Licensing Agreement March 22, 2023

              ASK
              US
              PHARMACOMPASS
              Upload
              your Pipeline Activity

              TaiGen Biotechnology

              Contact Supplier
              • Deals
              Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE
              Post an Enquiry Post an Enquiry
              Flag Taiwan
              Virtual Booth Virtual Booth
              Digital Content Digital Content

              TaiGen Partners with GPCR to Develop Burixafor & Taigexyn®

              Details:

              Under the terms of the agreement, GPCR Therapeutics will be wholly responsible for the development, registration, and commercialization of Taigexyn® in S. Korea and Burixafor worldwide.

              Lead Product(s): Burixafor

              Therapeutic Area: Immunology Product Name: TG-0054

              Highest Development Status: Phase II Product Type: Small molecule

              Partner/Sponsor/Collaborator: GPCR Therapeutics

              Deal Size: Undisclosed Upfront Cash: Undisclosed

              Deal Type: Agreement November 09, 2020

              ASK
              US
              PHARMACOMPASS
              Upload
              your Pipeline Activity

              TaiGen Biotechnology

              Contact Supplier
              • Development Update
              Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE
              Post an Enquiry Post an Enquiry
              Flag Taiwan
              Virtual Booth Virtual Booth
              Digital Content Digital Content

              TaiGen Announces FDA Approval of IND for Its Flu Antiviral TG-1000

              Details:

              TG-1000 is a novel pan-influenza antiviral, which interrupts viral replication and transmission via a cap-snatching mechanism and is able to do this effectively against influenza-A, influenza-B, avian flu H7N9, and Tamiflu-resistant viruses.

              Lead Product(s): TG-1000

              Therapeutic Area: Infections and Infectious Diseases Product Name: TG-1000

              Highest Development Status: Phase I Product Type: Undisclosed

              Partner/Sponsor/Collaborator: Not Applicable

              Deal Size: Not Applicable Upfront Cash: Not Applicable

              Deal Type: Not Applicable November 02, 2020

              ASK
              US
              PHARMACOMPASS
              Upload
              your Pipeline Activity

              TaiGen Biotechnology

              Contact Supplier
              • Development Update
              Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE
              Post an Enquiry Post an Enquiry
              Flag Taiwan
              Virtual Booth Virtual Booth
              Digital Content Digital Content

              TaiGen Filed U.S IND for Its Influenza Antiviral TG-1000

              Details:

              TG-1000 is a novel pan-influenza antiviral, which interrupts viral replication and transmission via a cap-snatching mechanism and is able to do this effectively against influenza-A, influenza-B, avian flu H7N9, and Tamiflu-resistant viruses.

              Lead Product(s): TG-1000

              Therapeutic Area: Infections and Infectious Diseases Product Name: TG-1000

              Highest Development Status: Phase I Product Type: Undisclosed

              Partner/Sponsor/Collaborator: Not Applicable

              Deal Size: Not Applicable Upfront Cash: Not Applicable

              Deal Type: Not Applicable October 05, 2020

              ASK
              US
              PHARMACOMPASS
              Upload
              your Pipeline Activity

              TaiGen Biotechnology

              Contact Supplier
              • Deals
              Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE
              Post an Enquiry Post an Enquiry
              Flag Taiwan
              Virtual Booth Virtual Booth
              Digital Content Digital Content

              TaiGen Out-Licensed Taigexyn® to Luminarie Canada for Canada, Australia and New Zealand

              Details:

              Under the terms of the agreement, Luminarie will be responsible for the development, registration and commercialization of Taigexyn® in the territory and assume all associated costs.

              Lead Product(s): Nemonoxacin

              Therapeutic Area: Infections and Infectious Diseases Product Name: Taigexyn

              Highest Development Status: Approved Product Type: Small molecule

              Partner/Sponsor/Collaborator: Luminarie

              Deal Size: Undisclosed Upfront Cash: Undisclosed

              Deal Type: Licensing Agreement September 30, 2020

              ASK
              US
              PHARMACOMPASS
              Upload
              your Pipeline Activity
              Minakem offers CDMO services for API & HPAPI, generics, regulatory expertise, track record performance & FDA & GMP certifications.
              ChemWerth works in generic API development & supply, non-infringement patent strategy development and regulatory support.
              Post Enquiry
              POST ENQUIRY